Literature DB >> 34127511

Radiation Therapy in Non-Small-Cell Lung Cancer.

Michael Dohopolski1, Sujana Gottumukkala1, Daniel Gomez2, Puneeth Iyengar1.   

Abstract

The management of non-small-cell lung cancer (NSCLC) varies according to stage. Surgical resection is reserved for operable patients with early-stage NSCLC, while high-dose target radiation-stereotactic body radiation therapy (SBRT)-is reserved for patients whose comorbidities prohibit them from a major surgical procedure. The treatment of locally advanced NSCLC (LA-NSCLC) is stratified according to resectability. Those with resectable disease may require additional treatments such as chemotherapy and radiation, while patients with unresectable disease will require definitive chemoradiation therapy with adjuvant durvalumab. Patients with limited metastatic disease benefit from the combination of SBRT and systemic therapy.
Copyright © 2021 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34127511      PMCID: PMC8485739          DOI: 10.1101/cshperspect.a037713

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  3 in total

1.  Elevated BTG2 improves the radiosensitivity of non-small cell lung cancer (NSCLC) through apoptosis.

Authors:  Changchun Zhu; Songling Zhang; Aiying Xue; Guoxing Feng; Saijun Fan
Journal:  Thorac Cancer       Date:  2022-04-07       Impact factor: 3.223

2.  Dysregulation of Pseudogenes/lncRNA-Hsa-miR-1-3p-PAICS Pathway Promotes the Development of NSCLC.

Authors:  Yichen Song; Zhiying Wang; Lewei He; Feidi Sun; Beilei Zhang; Fu Wang
Journal:  J Oncol       Date:  2022-08-30       Impact factor: 4.501

3.  The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma.

Authors:  Xin Tang; Jiaojiao Wu; Jiangtao Liang; Changfeng Yuan; Feng Shi; Zhongxiang Ding
Journal:  Front Oncol       Date:  2022-08-23       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.